Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms

Background Therapy related myeloid neoplasms (t-MNs) are complex diseases originating from an interplay between exogenous toxicities and a susceptible organism. It has been hypothesised that in a subset of cases t-MNs develop in the context of hereditary cancer predisposition syndromes. Methods The study systematically evaluated pedigrees of patients with t-MNs for cancer incidences and the possibility of a hereditary cancer predisposition syndrome. In addition, mutational analyses were performed using constitutional DNA from index patients, and deleterious heterozygous germline mutations were assessed for loss of heterozygosity in sorted leukaemic cells by single nucleotide polymorphism array. Results A nuclear pedigree was obtained in 51/53 patients with t-MNs resulting in a total of 828 individuals analysed. With a standardised incidence ratio of 1.03 (95% CI 0.74 to 1.39), the tumour incidence of first- degree relatives was not increased. However, six pedigrees were suggestive for a hereditary breast and ovarian cancer syndrome, three of a Li-Fraumeni like syndrome, and three index patients showed multiple primary neoplasms. Mutational analysis revealed two BRCA1 (c.3112G→T, c.5251C→T), one BRCA2 (c.4027A→G), two BARD1 (C557S) and four TP53 germline mutations (g.18508_18761delinsGCC, c.847C→T, c.845_848dupGGCG, c.1146delA) in nine of 53 (17%) index patients with t-MNs. Loss of heterozygosity in leukaemic cells was demonstrated for the BRCA1c.3112G→T and TP53c.845_848dupGGCG mutations, respectively. Conclusion It is concluded that a proportion of patients with t-MNs carry cancer susceptibility mutations which are likely to contribute to therapy related leukaemogenesis.

[1]  L. Larocca,et al.  Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia , 2006, British Journal of Cancer.

[2]  C. Guelly,et al.  Evaluation of mutations in the isocitrate dehydrogenase genes in therapy‐related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy , 2011, British journal of haematology.

[3]  B. Johansson,et al.  Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001 , 2002, Leukemia.

[4]  Adopted on March American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. LaCroix,et al.  Accuracy of reports of familial breast cancer in a case-control series. , 1995, Epidemiology.

[6]  B. Mukesh,et al.  Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Kere,et al.  Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies , 2006, Journal of Medical Genetics.

[8]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[9]  W. Oberaigner,et al.  Record Linkage in the Cancer Registry of Tyrol, Austria , 2005, Methods of Information in Medicine.

[10]  C. Bonaïti‐pellié,et al.  Sensitivity and predictive value of criteria for p53germline mutation screening , 2001, Journal of medical genetics.

[11]  M. Sauer,et al.  Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer , 2005, Journal of Medical Genetics.

[12]  Sonali M. Smith,et al.  Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.

[13]  A. Wölfler,et al.  Therapy‐related myeloid neoplasms: pathobiology and clinical characteristics , 2011, British journal of pharmacology.

[14]  J. Estève,et al.  Statistical Methods In Cancer Research , 2012 .

[15]  S. Uranüs,et al.  Hypersensitivity to alkylation treatment of primary fibroblasts from patients with therapy-related myeloid neoplasms. , 2012, Leukemia research.

[16]  N. Kröger,et al.  Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation , 2009, Haematologica.

[17]  T. Haferlach,et al.  Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. , 2007, Leukemia research.

[18]  G. Mills,et al.  Assessing BRCA carrier probabilities in extended families. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Kowalczykowski,et al.  Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms , 2011, Proceedings of the National Academy of Sciences.

[20]  N. Russell,et al.  Advances in the understanding of susceptibility to treatment‐related acute myeloid leukaemia , 2007, British journal of haematology.

[21]  A. Skol,et al.  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. , 2009, Blood.

[22]  J. Biegel,et al.  TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Estève,et al.  Statistical methods in cancer research. Volume IV. Descriptive epidemiology. , 1998, IARC scientific publications.

[24]  A. Levis,et al.  Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia , 2001, British journal of haematology.

[25]  S. Ben-Neriah,et al.  Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. , 1996, Blood.

[26]  Kum Kum Khanna,et al.  BRCA1-BARD1 Complexes Are Required for p53Ser-15 Phosphorylation and a G1/S Arrest following Ionizing Radiation-induced DNA Damage* , 2004, Journal of Biological Chemistry.

[27]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[28]  Catherine Bonaïti-Pellié,et al.  2009 version of the Chompret criteria for Li Fraumeni syndrome. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Eeles Germline mutations in the TP53 gene. , 1995, Cancer surveys.

[30]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Lynch,et al.  Hereditary Breast Cancer: Part I. Diagnosing Hereditary Breast Cancer Syndromes , 2008, The breast journal.

[32]  References , 1971 .

[33]  C. Jefford,et al.  Is there more to BARD1 than BRCA1? , 2006, Nature Reviews Cancer.

[34]  C. Jefford,et al.  Identification of BARD1 as mediator between proapoptotic stress and p53-dependent apoptosis. , 2001, Molecular cell.

[35]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[36]  S. Haque Ethics approval This study was conducted with the approval of the East London and City Health Authority Ethic Committee. Provenance and peer review Not commissioned; externally peer reviewed. , 2011 .

[37]  M. Sauer,et al.  Identification and characterization of missense alterations in the BRCA 1 associated RING domain ( BARD 1 ) gene in breast and ovarian cancer , 2005 .

[38]  D. Meek,et al.  Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. , 2010, Cellular signalling.

[39]  Ettore Appella,et al.  ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing Radiation* , 2002, The Journal of Biological Chemistry.

[40]  Dieter Niederacher,et al.  MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early‐onset cases , 2008, Human mutation.

[41]  J. Bartek,et al.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.